Smoking cessation support services at community pharmacies in the UK: A systematic review

Hellenic Journal of Cardiology

Volumn 57, Issue JANUARY-FEBRUARY, 2016, Pages 7-15

  Peletidi, Aliki ^a   Nabhani Gebara, Shereen ^a   Kayyali, Reem ^a  

^a KINGSTON UNIVERSITY   (United Kingdom)

Author keywords

Community pharmacy; Cost effectiveness; CVD prevention; England; Interventions; Pharmacy personnel; Scotland; Smoking cessation; UK

Indexed keywords

CARBON MONOXIDE; NICOTINE GUM;

CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; HUMAN; MEDICAL LITERATURE; NICOTINE REPLACEMENT THERAPY; OUTCOME ASSESSMENT; PHARMACIST; PHARMACY; PUBLIC HEALTH; PUBLICATION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SYSTEMATIC REVIEW; UNITED KINGDOM; ADVERSE EFFECTS; COST BENEFIT ANALYSIS; ECONOMICS; PATIENT EDUCATION; PROCEDURES; SMOKING;

COST-BENEFIT ANALYSIS; HUMANS; PATIENT EDUCATION AS TOPIC; PHARMACIES; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; UNITED KINGDOM;

EID: 84957644782     PISSN: 11099666     EISSN: 22415955     Source Type: Journal    
DOI: 10.1016/s1109-9666(16)30012-4     Document Type: Review

References (16)

1. National Centre for Health Outcomes Development (2008-09) Statistics [Internet]. Available from: www.nchod.nhs.uk.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-2128.
3. Cannon CP. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone. 2007; 8: 11-28.
4. Panagiotakos DB, Georgousopoulou EN, Fitzgerald AP, Pitsavos C, Stefanadis C. Validation of the HellenicSCORE (a Calibration of the ESC SCORE Project) regarding 10-year risk of fatal cardiovascular disease in greece. Hellenic J Cardiol. 2015; 56: 302-308.
5. Stead LF, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007; (3): CD005231.
6. Chrysohoou C. Are cardiac risk scores useful in daily clinical practice? Hellenic J Cardiol. 2015; 56: 309-310.
7. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD003698.
8. Ioakeimidis N, Vlachopoulos C, Tousoulis D. Efficacy and safety of electronic cigarette for smoking cessation: a critical approach. Hellenic J Cardiol. 2016; 57: 1-6.
9. Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy. 2007; 27: 1040-1051.
10. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Health Care. York: University of York; 2009.
11. Bauld L, Chesterman J, Ferguson J, Judge K. A comparison of the effectiveness of group-based and pharmacy-led smoking cessation treatment in Glasgow. Addiction. 2009; 104: 308-316.
12. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001; 96: 325-331.
13. Sinclair HK, Bond CM, Lennox AS, Silcock J, Winfield AJ, Donnan PT. Training pharmacists and pharmacy assistants in the stage-of-change model of smoking cessation: a randomised controlled trial in Scotland. Tob Control. 1998; 7: 253-261.
14. Anderson C. A controlled study of the effect of a health promotion training scheme on pharmacists’ advice about smoking cessation. J Soc Adm Pharm. 1995; 12: 115-124.
15. Boyd KA, Briggs AH. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction. 2009; 104: 317-325.
16. Bauld L, Boyd KA, Briggs AH, et al. One-year outcomes and a cost-effectiveness analysis for smokers accessing groupbased and pharmacy-led cessation services. Nicotine Tob Res. 2011; 13: 135-145.